All Outputs (2)

Impact of extended Elexacaftor/Tezacaftor/Ivacaftor therapy on the gut microbiome in cystic fibrosis (2024)
Journal Article
Marsh, R., Santos, C. D., Yule, A., Dellschaft, N. S., Hoad, C. L., Ng, C., Major, G., Smyth, A. R., Rivett, D., & van der Gast, C. (2024). Impact of extended Elexacaftor/Tezacaftor/Ivacaftor therapy on the gut microbiome in cystic fibrosis. Journal of Cystic Fibrosis, https://doi.org/10.1016/j.jcf.2024.05.002

Background There is a paucity of knowledge on the longer-term effects of CF transmembrane conductance regulator (CFTR) modulator therapies upon the gut microbiome and associated outcomes. In a pilot study, we investigated longitudinal Elexacaftor/Te... Read More about Impact of extended Elexacaftor/Tezacaftor/Ivacaftor therapy on the gut microbiome in cystic fibrosis.

Thinking outside the box: a review of gastrointestinal symptoms and complications in cystic fibrosis (2023)
Journal Article
Yule, A., Sills, D., Smith, S., Spiller, R., & Smyth, A. R. (2023). Thinking outside the box: a review of gastrointestinal symptoms and complications in cystic fibrosis. Expert Review of Respiratory Medicine, 17(7), 547-561. https://doi.org/10.1080/17476348.2023.2228194

Introduction Gastrointestinal (GI)-related symptoms, complications, and comorbidities in cystic fibrosis (CF) are common and research to reduce their burden is a priority for the CF community. To enable future research, this review aimed to summariz... Read More about Thinking outside the box: a review of gastrointestinal symptoms and complications in cystic fibrosis.